Physician

Amy Susan Garwood, M.D.

According to 2025 Medicare claims, Amy Garwood, M.D. (NPI: 1649227646) practices rheumatology in the Lincoln, NE market, with the plurality of this provider's patient population coming from Lancaster, NE. This provider's primary affiliated billing organization is RHEUMATOLOGY & OSTEOPOROSIS SERVICES, P.C. (NPI: 1174737597; TIN: 201212442) and primary practice location at 68510-2466. Garwood is affiliated with the NPG Health Collaborative LLC (ACO ID: A3287), Bryan Health Connect ACO, LLC (ACO ID: A4573), and Main Street Rural Health Maple ACO LLC (ACO ID: A5401), participating under the MSSP model.

Garwood's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 696 traditional Medicare patients, billed 269,927 HCPCS/CPT codes, and received $2,253,278 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,572 prescription claims across 485 beneficiaries totaling $810,536 in drug costs, led by Humira(Cf) Pen (Adalimumab). 2017 DME data shows 22 claims. Open Payments data shows 1 records totaling $17. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $282,894 to $2,253,278. Concurrently, Part D prescription costs did not follow a clear longitudinal pattern. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $3,976 and ending at $5,299.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	590	21,081	$282,894
2016	666	34,710	$412,197
2017	540	14,978	$224,004
2018	679	26,372	$360,242
2019	615	15,745	$275,729
2020	601	31,694	$481,904
2021	559	26,006	$354,469
2022	604	49,341	$541,895
2023	692	181,129	$1,526,584
2024	696	269,927	$2,253,278

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	374	3,190	$757,969
2016	418	4,042	$878,130
2017	411	3,801	$806,484
2018	421	3,406	$808,281
2019	450	3,299	$943,693
2020	473	3,434	$837,442
2021	499	3,358	$576,296
2022	530	3,394	$656,922
2023	540	2,879	$581,395
2024	485	2,572	$810,536

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	22	$735
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	210	268	$87
96401	Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle	177	399	$51
J0897	Injection, denosumab, 1 mg	147	10,200	$21
96372	Injection of drug or substance under skin or into muscle	212	751	$10
J3111	Injection, romosozumab-aqqg, 1 mg	163	143,220	$9

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Humira(Cf) Pen	Adalimumab	25	868	$229,764
Cosentyx Sensoready (2 Pens)	Secukinumab	14	392	$146,118
Otezla	Apremilast	21	630	$114,815
Actemra	Tocilizumab	13	364	$62,898
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	478	28,412	$20,143

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	1	$17	Amgen Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Amy Susan Garwood, M.D.?

Tedicare shows public-source Medicare data for Amy Susan Garwood, M.D. (NPI 1649227646), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Amy Susan Garwood, M.D. have ACO affiliation data?

Amy Susan Garwood, M.D. is shown with ACO affiliation data for NPG Health Collaborative LLC (MSSP, ACO ID A3287), Bryan Health Connect ACO, LLC (MSSP, ACO ID A4573), and Main Street Rural Health Maple ACO LLC (MSSP, ACO ID A5401).

What billing organization is linked to Amy Susan Garwood, M.D.?

Amy Susan Garwood, M.D. is linked to RHEUMATOLOGY & OSTEOPOROSIS SERVICES, P.C. (billing NPI 1174737597) in the available physician profile data.

Does Amy Susan Garwood, M.D. have Open Payments data?

Amy Susan Garwood, M.D. has 1 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.